Lansoprazole Capsules
ID: SPE2D2-25-R-0005Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/4b2ebef985094dbba1902b0b075de1c8/view
Timeline
    Description

    The Defense Logistics Agency (DLA) is soliciting offers for the procurement of Lansoprazole DR 30MG capsules, a pharmaceutical product essential for treating various gastrointestinal conditions. This solicitation outlines the requirements for contractors to submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS), emphasizing compliance with Federal Acquisition Regulation (FAR) clauses and ethical business practices. The procurement is critical for maintaining the supply of necessary medications to support military personnel, ensuring adherence to stringent quality and legal standards. Interested contractors should direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil, with submissions due by the specified deadline in the solicitation document.

    Files
    Title
    Posted
    Solicitation Lansoprazole SPE2D2-25-R-0005.pdf
    The document is a solicitation (SPE2D2-24-R-0005) issued by the Defense Logistics Agency, detailing the procurement of certain pharmaceutical products, specifically Lansoprazole DR 30MG capsules, with a schedule for potential deliveries across multiple years. It outlines essential submission instructions for contractors to electronically submit their offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) and emphasizes that late submissions will not be accepted. The inclusion of various Federal Acquisition Regulation (FAR) clauses mandates compliance with procurement ethics, subcontracting plans, and other ethical business practices. Key sections of the document describe the requirements for bidders, including documenting qualifications, pricing proposals, and compliance with contract terms and conditions. It mandates reporting on subcontracting goals and contractor performance evaluations through online systems. The document also highlights the prohibitions on acquiring telecommunications equipment from certain foreign entities, ensuring that contractors meet stringent quality, legal, and ethical standards. Overall, it demonstrates the government's structured approach to securing pharmaceutical products while adhering to regulations and best practices in procurement.
    Lifecycle
    Title
    Type
    Lansoprazole Capsules
    Currently viewing
    Solicitation
    Lansoprazole Capsules
    Presolicitation
    Similar Opportunities
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Pantoprazole DR Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Rabeprazole Sodium DR
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA Troop Support), is seeking suppliers for Rabeprazole Sodium DR, a pharmaceutical product essential for various medical treatments. This procurement falls under the NAICS code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is classified under the PSC code 6505 for Drugs and Biologicals. Rabeprazole Sodium is commonly used to treat conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers, highlighting its importance in military healthcare. Interested vendors can reach out to Trong Nguyen at Trong.Nguyen@dla.mil or call 215-737-4197 for further details, while Jason Wray is also available at jason.wray@dla.mil or 215-737-0614 for additional inquiries.
    Telmisartan Tablets
    Buyer not available
    The Defense Logistics Agency (DLA) is soliciting proposals for the procurement of Telmisartan Tablets, a pharmaceutical product essential for various medical applications, under Solicitation No. SPE2D2-24-R-0015. The contract aims to secure a reliable supply of these tablets in multiple dosages over several years, emphasizing compliance with federal regulations, including the necessity for a Subcontracting Plan for large businesses and adherence to various Federal Acquisition Regulation (FAR) clauses. Interested contractors should note that the submission deadline has been extended to February 28, 2025, at 3:00 PM EST, and are encouraged to contact Courtney Hunter-Stangler at Courtney.Hunter-Stangler@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries.
    Rabeprazole Sodium Delayed Release Tablets
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Famotidine
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Famotidine, a drug used to treat ulcers and gastroesophageal reflux disease (GERD). The contract will include Famotidine 20 MG tablets in various bottle sizes and Famotidine 40 MG tablets in different bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The annual usage estimates will be provided in the solicitation. The solicitation is expected to be posted on the DLA Bid Board System (DIBBS) and SAM.gov. For any questions or comments, interested parties should contact Kristen Baraniewicz. The projected solicitation date is August 2022, but DLA reserves the right to issue the solicitation before or after that date.
    LANSOPRAZOLE NATIONAL CONTRACT MODIFICATION
    Buyer not available
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is issuing a modification to the LANSOPRAZOLE NATIONAL CONTRACT. This modification aims to incorporate additional clauses to the existing contract. Lansoprazole is a medication used to treat stomach and esophagus problems such as acid reflux, ulcers, and gastroesophageal reflux disease (GERD). It belongs to a class of drugs known as proton pump inhibitors and helps reduce the amount of acid produced in the stomach. The modification to the contract will include the addition of specific clauses that may address various aspects such as pricing, delivery schedules, quality control, or any other relevant terms and conditions. For more information or inquiries, please contact Denise Taubman at DENISE.TAUBMAN@DLA.MIL or 2157378677.
    Rizatriptan Benzoate
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.
    Repaglinide
    Buyer not available
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.
    REQUEST FOR INFORMATION (RFI) FOR MARKET RESEARCH FOR THE MEDICAL/SURGICAL PRIME VENDOR PROGRAM - DLA TROOP SUPPORT
    Buyer not available
    The Defense Logistics Agency (DLA) is conducting a Request for Information (RFI) to gather market research for the Medical Surgical Prime Vendor Program (Med/Surg PV), aimed at developing an acquisition strategy for a long-term, indefinite quantity contract. This initiative is critical for providing a comprehensive range of medical and surgical supplies to designated Medical Treatment Facilities (MTFs) through a single distribution channel, ensuring next-day delivery of both brand name and generic products. Interested vendors are invited to respond to the RFI by February 28, 2025, with submissions directed to Beatrice Lopez-Pollard, Contracting Officer, via mail or email at beatrice.lopez-pollard@dla.mil. The information collected will inform the contract formation process while safeguarding proprietary submissions.